12 Week Comparison of 5 Mcg and 10 Mcg of Tiotropium / Respimat, Placebo and Ipratropium MDI in COPD

Trough FEV1 response

Time frame: after 1, 4 and 8 weeks

Trough FVC response

Time frame: after 1, 4, 8 and 12 weeks

FEV1 and FVC area under the curve (AUC)0-6h and peak response

Time frame: after 0, 1, 4, 8 and 12 weeks

Individual FEV1 and FVC measurements

Time frame: during 12 weeks

Onset and duration of therapeutic response and percentage of responders

Time frame: after 0 and 12 weeks

Weekly mean pre-dose morning and evening PEFR (peak expiratory flow rate)

Time frame: up to 12 weeks

Weekly mean number of occasions of rescue therapy used per day (PRN salbutamol)

Time frame: up to 12 weeks

COPD symptom scores (wheezing, shortness of breath, coughing and tightness of chest)

Time frame: up to 15 weeks

Physician's Global Evaluation

Time frame: up to 15 weeks

Number of patients with at least one exacerbation of COPD

Time frame: up to 15 weeks